Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

NCT06346509 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Participants

Interventions

DRUG: PORT-77
DRUG: Placebo

Sponsor

Portal Therapeutics, Inc.